GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Essex Bio-Technology Ltd (HKSE:01061) » Definitions » Net Income

Essex Bio-Technology (HKSE:01061) Net Income : HK$275 Mil (TTM As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Essex Bio-Technology Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Essex Bio-Technology's Net Income for the six months ended in Dec. 2023 was HK$105 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was HK$275 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Essex Bio-Technology's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was HK$0.18.


Essex Bio-Technology Net Income Historical Data

The historical data trend for Essex Bio-Technology's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Essex Bio-Technology Net Income Chart

Essex Bio-Technology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 302.50 218.93 345.97 225.41 275.26

Essex Bio-Technology Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 183.78 139.23 86.18 169.81 105.45

Essex Bio-Technology Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Essex Bio-Technology's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

Net Income(A: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=346.014+-70.755+0+0.00099999999997635
=275

Essex Bio-Technology's Net Income for the quarter that ended in Dec. 2023 is calculated as

Net Income(Q: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=141.159+-35.711+0+0.0010000000000048
=105

Net Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$275 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Essex Bio-Technology  (HKSE:01061) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Essex Bio-Technology's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Essex Bio-Technology Net Income Related Terms

Thank you for viewing the detailed overview of Essex Bio-Technology's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Essex Bio-Technology (HKSE:01061) Business Description

Traded in Other Exchanges
N/A
Address
No. 88, Keji 6th Road, Hi-Tech Zone, Guangdong, Zhuhai, CHN
Essex Bio-Technology Ltd is principally engaged in investment holding and development, manufacture and sale of biologic drugs in the People's Republic of China. The company is made up of segments of Ophthalmology products and Surgical products. Its products under Ophthalmology include the Beifushu series, Tobramycin Eye Drops, Levofloxacin Eye Drops, Sodium Hyaluronate Eye Drops. The products under Surgical include the Beifuji series, Carisolv dental caries removal gel and mouth wash. The majority of the groups revenue comes from PRC.
Executives
Lauw Hui Kian
Ngiam Mia Je Patrick
Ngiam Mia Kiat Benjamin 2101 Beneficial owner

Essex Bio-Technology (HKSE:01061) Headlines

No Headlines